Figure 2.
Tet2 overexpression increases T-ALL latency in CD2-LMO2tg mice. (A) Schematic overview of breeding scheme resulting in CD2-iCretg/+;R26-Tet2tg/tg mice. (B) Aging cohort of CD2-Lmo2tg/+ (=Lmo2) (n = 13, median survival 201 days) and CD2-iCretg/+CD2-Lmo2tg/+R26-Tet2tg/tg (=Lmo2-Tet2) (n = 13, median survival 266 days) mice (P = .0226). (C) Tet2 mRNA expression in thymi of Lmo2 (n = 12) and Lmo2-Tet2 mice (n = 11) (P = .0045). (D) Aging cohort of Lck-Cretg/+Ptenfl/flR26-Tet2wt/wt (=Pten) (n = 11, median survival 75 days) and Lck-Cretg/+Ptenfl/flR26-Tet2tg/tg (=Pten-Tet2) (n = 11, median survial 87 days) mice (P = .4508). (E) Tet2 mRNA expression in thymi of Pten (n = 10) and Pten-Tet2 (n = 10) mice (P = .0138).

Tet2 overexpression increases T-ALL latency in CD2-LMO2tg mice. (A) Schematic overview of breeding scheme resulting in CD2-iCretg/+;R26-Tet2tg/tg mice. (B) Aging cohort of CD2-Lmo2tg/+ (=Lmo2) (n = 13, median survival 201 days) and CD2-iCretg/+CD2-Lmo2tg/+R26-Tet2tg/tg (=Lmo2-Tet2) (n = 13, median survival 266 days) mice (P = .0226). (C) Tet2 mRNA expression in thymi of Lmo2 (n = 12) and Lmo2-Tet2 mice (n = 11) (P = .0045). (D) Aging cohort of Lck-Cretg/+Ptenfl/flR26-Tet2wt/wt (=Pten) (n = 11, median survival 75 days) and Lck-Cretg/+Ptenfl/flR26-Tet2tg/tg (=Pten-Tet2) (n = 11, median survial 87 days) mice (P = .4508). (E) Tet2 mRNA expression in thymi of Pten (n = 10) and Pten-Tet2 (n = 10) mice (P = .0138).

Close Modal

or Create an Account

Close Modal
Close Modal